Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Expression of DOG1, CD117 and PDGFRA in Gastrointestinal Stromal Tumors and Correlations with Clinicopathology

  • Sun, Xiu-Wei (Department of Gastroenterology, the Third Affiliated Hospital of Harbin Medical University) ;
  • Feng, Zhan-Jun (Department of Gastroenterology, the Third Affiliated Hospital of Harbin Medical University) ;
  • Huang, Peng (Department of Gastroenterology, the Third Affiliated Hospital of Harbin Medical University) ;
  • Hao, Wang (Department of Gastroenterology, the Third Affiliated Hospital of Harbin Medical University) ;
  • Sui, Xing-Ling (Department of Gastroenterology, the Third Affiliated Hospital of Harbin Medical University)
  • Published : 2012.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To discuss the significance of DOG1, CD117 and PDGFRA in the diagnosis of gastrointestinal stromal tumors (GISTs), and analyze their correlations with clinicopathological features and risk ranking. Method: DOG1, CD117 and PDGFRA were detected with IHC Envision ldpe-g-nvp in 63 GISTs and 43 cases of non-GISTs, and analyzed for relations with clinicopathological factors (gender, age, location, tumor size, mitotic phase, histology) and risk degree. Results: The positive expression rate of DOG1, CD117 and PDGFRA in GISTs was 84.1% (53/63), 90.5% (57/63), 53.2% (33/63), respectively. Among the 6 CD117 negative cases, all were DOG1 positive and 5 were PDGFRA positive. Rates in patients with non-GISTs was 11.6%, 16.3%, 6.98%, respectively. Expression of DOG1 and PDGFRA demonstrated no significant variation with gender, age, position, tumor size, mitotic phase, histology, and risk rank. However, CD117 was related with position and histology (P=0.008 and P=0.045), those in the mesentery having a higher positive rate than those derived from stomach, small intestine, colon and rectum (50.0% vs 94.7%, P=0.008). Furthermore CD117 was also highly expressed in spindle and epithele types. Conclusions: DOG1 had a good sensitivity and specificity as a kind of newly discovered marker, especially for KIT negative GISTs. However, DOG1, CD117 and PDGFRA cannot be used for assessing the rish of patients.

Keywords

References

  1. Borquez Ma P, Neveu CR (2008). Gastrointestinal stromal tumors. An update. Rev Med Chil, 136, 921-9.
  2. Caputo A, Caci E, Ferrera L, et al (2008). TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science, 322, 590-4. https://doi.org/10.1126/science.1163518
  3. Carles A, Millon R, Cromer A, et al (2006). Head and neck squamous cell carcinoma transcriptome analysis by comprehensive validated differential display. Oncogene, 25, 1821-31. https://doi.org/10.1038/sj.onc.1209203
  4. Corless CL, Heinrich MC (2008). Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol, 3, 557-86. https://doi.org/10.1146/annurev.pathmechdis.3.121806.151538
  5. Dow N, Giblen G, Sobin LH, et al (2006). Gastrointestinal stromal tumors, differential Diagnosis. Semin Diagn Pathol, 23, 111-9. https://doi.org/10.1053/j.semdp.2006.09.002
  6. Espinosa I, Lee CH, Kim MK, et al (2008). A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol, 32, 210-8. https://doi.org/10.1097/PAS.0b013e3181238cec
  7. Heinrich MC, Corless CL, Duensing A, et al (2003). PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 299, 708-10. https://doi.org/10.1126/science.1079666
  8. Hornick JL, Fletcher CD (2002). Immunohistochemical staining for KIT(CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol, 117, 188-93. https://doi.org/10.1309/LX9U-F7P0-UWDH-8Y6R
  9. Joensuu H (2008). Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol, 39, 1411-9. https://doi.org/10.1016/j.humpath.2008.06.025
  10. Kang YN, Jung HR, Hwang I (2010). Clinicopathological and immunohistochemical features of gastrointestinal stromal tumors. Cancer Res Treat, 42, 135-43. https://doi.org/10.4143/crt.2010.42.3.135
  11. Lopes LF, West RB, Bacchi LM, et al (2010). DOG1 for the diagnosis of gastrointestinal stromal tumor (GIST), Comparison between 2 different antibodies. Appl Immunohistochem Mol Morphol, 18, 333-7. https://doi.org/10.1097/PAI.0b013e3181d27ec8
  12. Medeiros F, Corless CL, Duensing A, et al (2004). KIT-negative gastrointestinal stromal tumors, proof of concept and therapeutic implications. Am J Surg Pathol, 28, 889-94. https://doi.org/10.1097/00000478-200407000-00007
  13. Miettinen M, Lasota J (2006). Gastrointestial stromal tumors, review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med, 130, 1466-78.
  14. Miettinen M, Sobin LH, Lasota J (2005). Gastrointestinal stromal tumors of the stomach, a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol, 29, 52-68. https://doi.org/10.1097/01.pas.0000146010.92933.de
  15. Miettinen M, Wang ZF, Lasota J (2009). DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors, a study of 1840 cases. Am J Surg Pathol, 33, 1401-8. https://doi.org/10.1097/PAS.0b013e3181a90e1a
  16. Miwa S, Nakajima T, Murai Y, et al (2008). Mutation assay of the novel gene DOG1 in gastrointestinal stromal tumors (GISTs). J Gastroenterol, 43, 531-7. https://doi.org/10.1007/s00535-008-2195-4
  17. Novelli M, Rossi S, Rodriguez-Justo M, et al (2010). DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology, 57, 259-70. https://doi.org/10.1111/j.1365-2559.2010.03624.x
  18. Pauls K, Merkelbach-Bruse S, Thal D, et al (2005). PDGFRalphaand c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features. Histopathology, 46, 166-75. https://doi.org/10.1111/j.1365-2559.2005.02061.x
  19. Peterson MR, Piao Z, Weidner N, et al (2006). Strong PDGFRA positivity is seen in GISTs but not in other intra-abdominal mesenchymal tumors, Immunohistochemical and mutational analyses. Appl Immunohistochem Mol Morphol, 14, 390-6. https://doi.org/10.1097/01.pai.0000203038.33414.a3
  20. Rossi CR, Mocellin S, Mencarelli R, et al (2003). Gastrointestinal stromal tumors, from a surgical to a molecular approach. Int J Cancer, 107, 171-6. https://doi.org/10.1002/ijc.11374
  21. Stamatakos M, Douzinas E, Stefanaki C, et al (2009). Gastrointestinal stromal tumor. World J Surg Oncol, 7, 61. https://doi.org/10.1186/1477-7819-7-61
  22. Rossi G, Valli R, Bertolini F, et al (2005). PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of gastrointestinal tract. Histopathology, 46, 522-31. https://doi.org/10.1111/j.1365-2559.2005.02128.x
  23. West RB, Corless CL, Chen X, et al (2004). The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors orrespective of KIT or PDGFRA mutations status. Am J Pathol, 165, 107-13. https://doi.org/10.1016/S0002-9440(10)63279-8
  24. Yang YD, Cho H, Koo JY, et al (2008). TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature, 455, 1210-5. https://doi.org/10.1038/nature07313

Cited by

  1. Gastrointestinal Stromal Tumors: A Clinicopathologic and Risk Stratification Study of 255 Cases from Pakistan and Review of Literature vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.4873
  2. Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations vol.16, pp.1, 2016, https://doi.org/10.1186/s12885-016-2111-x